Clinical Trial

TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated August 12, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a multicenter, open Phase Ib/II clinical study evaluating the safety and efficacy of TQB2922 in combination with TAS-102±bevacizumab in subjects with RAS/BRAF wild-type unresectable locally advanced or metastatic colorectal cancer that has failed treatment with oxaliplatin, fluorouracil-based and irinotecan.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-23.
Status change: Not Yet Recruiting → Recruiting 2025-08-11
Trial Details
NCT Number NCT07044908
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Conditions RAS/BRAF Wild Type Colorectal Cancer
Enrollment 72 participants
Start Date 2025-07-30
Primary Completion 2026-07 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2025-08-12